quilt-3.032: a multicenter clinical trial of intravesical bacillus calmette-guerin (bcg) in combination with alt-803 (n-803) in patients with bcg unresponsive high grade non-muscle invasive bladder cancer

Conditions: Bladder Cancer

Summary: this is a phase ii/iii, open-label, single-arm, multicenter study of intravesical bcg plus n-803 or n-803 only in patients with bcg unresponsive high grade non-muscle invasive bladder cancer (nmibc). all patients treated in the study will receive via a urinary catheter in the bladder, bcg plus n-803 or n-803 only weekly for 6 consecutive weeks (initial induction treatment period). after the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at month 3. eligible patients will continue to receive maintenance treatment in the third treatment period at months 6, 9, 12, and 18. eligible patients have the option to receive maintenance treatment in the fourth treatment period at months 24, 30, and 36. the study duration is 60 months.


Eligibility criteria:
inclusion criteria: * male or female patients 18 years of age or older * histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology). * histologically confirmed presence of bcg-unresponsive cis (with or without ta or t1 disease) or histologically confirmed presence of bcg-unresponsive high-grade ta or t1 disease. * absence of resectable disease after transurethral resection (turbt) procedures (residual carcinoma in situ (cis) acceptable; patients with t1 tumors must undergo repeat resection and biopsy \[inclusive of muscularis propria\] if initial biopsy did not include muscularis propria). patients with high-grade ta and/or t1 disease should have complete resection before study treatment. * bcg-unresponsive disease as defined as: (a) persistent or recurrent cis (+/- recurrent ta/t1 disease) within 12 months of receiving adequate bcg (at least five of six doses doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course); or (b) recurrent high-grade ta/t1 disease within 6 months of completion of adequate bcg (at least five of six doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course); or (c) t1 high-grade disease at the first evaluation following an induction bcg course alone (at least five of six doses of an initial induction course). * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * voluntary written informed consent and hipaa authorization and agree to comply with all protocol-specified procedures and follow-up evaluations exclusion criteria: * recurrence of bcg unresponsive ta/t1 disease (without presence of cis) \> 6 months after last bcg instillation or bcg unresponsive cis \> 12 months after last bcg instillation. * life expectancy \<2 years * any of the following clinical laboratory values at the time of enrollment: (1) absolute neutrophil count (anc) \<800/µl or (2) platelets \< 50,000/µl * liver function abnormalities as indicated by ongoing hepatic enzyme elevation (ast or alt) \>2 times upper limit of normal (uln) * renal insufficiency as indicated by a creatinine level \>3 times uln * history of or evidence of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer (inclusive of the prostatic urethra); or any other cancer within the past 5 years that is progressing or requires active treatment. exceptions are adequately treated basal cell or squamous cell skin cancer that has undergone potentially curative therapy or in situ cervical cancer; and adequately treated stage i or ii cancer or stable prostate cancer from which the patient is currently in complete remission, and is under active surveillance or hormone control. * symptomatic congestive heart failure (chf), new york heart association (nyha) class iii or iv heart failure or other clinical signs of severe cardiac dysfunction * severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry * history or evidence of uncontrollable central nervous system (cns) disease * active systemic infection requiring parenteral antibiotic therapy. all prior infections must have resolved following optimal therapy * concurrent febrile illness, active urinary tract infection, active tuberculosis, a history of hypotension or anaphylactic reactions * ongoing chronic systemic steroid therapy required (\>10 mg oral prednisone daily or equivalent) * women who are pregnant or nursing. female patients of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (e.g., hysterectomy or tubal ligation). women of childbearing potential are defined as any female who has experienced menarche and who is not permanently sterile or postmenopausal. postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug. * patients currently receiving investigational or commercial anti-cancer agents or anti-cancer therapies other than bcg, alt-803 and supportive care therapies for active disease. * concurrent use of other investigational agents (not including fda authorized drugs for the prevention and treatment of covid-19). * other illness or condition, including laboratory abnormalities, which in the opinion of the investigator would exclude the patient from participating in this study. this includes, but is not limited to, serious medical conditions or psychiatric illness likely to interfere with participation in the study.

Keywords: bcg bladder cancer immunotherapy interleukin-15 intravesical non-muscle invasive nmibc